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abstract
The EORTC Infectious Disease Group (IDG) and its forerunners, the International
Antimicrobial Therapy Cooperative Group (IATCG) and the Invasive Fungal Infection
Group (IFIG), have helped drive and develop clinical practice in the management
of bacterial and fungal infectious diseases. Besides undertaking seminal studies,
the group in its various forms has played a key role in understanding the nature
and management of the infectious complications that arise during the treatment of
cancer, particularly hematological malignancies. The IATCG was also instrumental
in setting the stage for large randomized controlled trials to address therapies for
dealing with infections that developed during neutropenia. The three most important
achievements of the group were in ﬁnding a rational basis for managing bacterial and
fungal infections, the establishment of disease deﬁnitions, and the development of
the guidelines.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The EORTC Infectious Disease Group (IDG) and its
forerunners, the International Antimicrobial Therapy
Cooperative Group (IATCG) and the Invasive Fungal
Infection Group (IFIG), have helped drive and develop
clinical practice in the management of bacterial and
fungal infectious diseases. Besides undertaking seminal
studies, the group in its various forms has played a key
role in understanding the nature and management of the
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infectious complications that arise during the treatment
of cancer, particularly hematological malignancies. The
IATCG was also instrumental in setting the stage for
large randomized controlled trials to address therapies
for dealing with infections that developed during
neutropenia.
The IATCG activities started in 1973; a landmark study
was published in 1978 that involved 625 patients and
showed that infections due to Gram-negative bacteria
could be managed best with a beta-lactam antibiotic
and an aminoglycoside. The study demonstrated that
continuing the aminoglycoside was not always neces-
sary, thereby reducing the risk of toxicity. The group also
succeeded in joining forces ﬁrst with the National Cancer
Institute of Canada-Clinical Trials Group and later on
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Table 1 – Response rates in granulocytopenic patients with cancer who were treated with antibiotics
for microbiologically documented infections 1
Pathogen Carbenicillin plus
cephalothina
Carbenicillin plus
gentamicina
Gentamicin plus
cephalothin
Total
Pseudomonas aeruginosa 4/8 (50) 10/16 (63) 5/13 (38) 19/37 (51)
Klebsiella species 9/15 (60) 12/22 (55) 6/17(35) 27/54 (50)
Escherichia coli 8/18 (44) 22/30 (73) 18/27 (67) 48/75 (64)
Other Gram-negative bacilli 4/9 (44) 8/15 (53) 4/7 (57) 16/31 (52)
Total Gram-negative bacilli 25/50 (50) 52/83 (63) 33/64 (52) 110/197 (56)
Staphylococcus aureus 18/22 (82) 12/13 (92) 13/19 (68) 43/54 (80)
Other Gram-positive cocci 5/11 (46) 5/8 (63) 7/11 (64) 17/30 (57)
Total Gram-positive cocci 23/33 (70) 17/21 (81) 20/30 (67) 60/84 (71)
Other bacteria 1/2 2/3 6/8 9/13
Total of all pathogens 49/85 (58) 71/107 (66) 59/102 (58) 179/294 (61)
Data are number of patients with response/number tested (percentage). Some patients were infected withmultiple pathogens.
a Ticarcillin was used instead of carbenicillin in approximately one-third of the cases.
with the Gruppo Italiano Malattie Ematologiche Maligne
dell’Adulto Infection Program (GIMEMA). The IATCG
became renowned throughout the scientiﬁc community
and also helped establish a clear link between supportive
care and the EORTC.
The IFIG was founded in 1992. In a similar vein as
the IATCG, the IFIG completed another landmark study
that established the standard of care for treating invasive
aspergillosis, a disease that grew in prominence due, in
part, to the success in managing bacterial infections.
This study also helped forge a link with the Mycosis
Study Group (MSG) of the USA which proved fruitful
in the development of consistent deﬁnitions of the
invasive fungal disease and in devising response criteria
to therapy that have been adopted by journals, regulatory
authorities and the scientiﬁc community as a whole.
In 2005, the IATCG and the IFIG were merged in a
unique group aimed at studying all types of infectious
complications in cancer patients, the IDG. Last but
not least, the IDG has been an active partner of the
European Leukaemia Network, the European Group for
Blood and MarrowTransplantation, and the International
Immunocompromised Host Society in producing the
European Conference on Infections in Leukemia (ECIL)
guidelines for managing viral, bacterial, and fungal
diseases. The ECIL has convened every two years since
2005 with the next meeting planned for 2013. The three
most important achievements of the group in the ﬁeld of
managing bacterial and fungal infections, establishment
of disease deﬁnitions, and the development of the
guidelines are summarized below.
2. Achievements in bacterial infections
In the 1970’s, managing infections arising from neu-
tropenia was challenging and, though there were many
antimicrobial drugs available and the most common
causes of bacterial infection were known, there was no
standard of care. It was already known that mortality
due to Gram-negative bacterial infections could best be
reduced by starting therapy empirically as soon as a
neutropenic patient became febrile. 1 Formed in 1973, the
IATCG initiated a study of three different antimicrobial
regimens for patients with cancer or aplastic anemia,
who were granulocytopenic and who had developed fever
that had no obvious non-infective cause. 2
The aims of the study were three-fold: (1) to deﬁne
the types of infection that occur, (2) to evaluate
predisposing factors, and (3) to compare the efﬁcacy and
toxicity of three commonly utilized empirical antibiotic
combinations, one a so-called double beta-lactam
regimen, carbenicillin or ticarcillin plus cephalothin,
and two different beta-lactam-aminoglycoside regimens,
namely, carbenicillin or ticarcillin plus gentamicin, and
cephalothin plus gentamicin (Table 1). Besides showing
that a combination of carbenicillin (or ticarcillin) and
an aminoglycoside achieved higher response rates, the
study noted that almost 1 in 5 fevers were probably
not due to infection and another 1 in 5 could only be
considered possibly due to infection. However, since at
the onset of fever there was no way of distinguishing
between these fevers and those due to clinically
deﬁned or microbiologically deﬁned infections, patients
should be treated promptly at the onset of fever to
reduce mortality due to infections caused by Gram-
negative bacteria such as Escherichia coli and Pseudomonas
aeruginosa. 1
The next IATCG study compared ceftazidime combined
with a short or long course of amikacin for empirical
therapy and conﬁrmed that a short course of an
aminoglycoside was as effective and less toxic than
a conventional long course of the combination for
the empirical therapy of Gram-negative bacteremia of
patients with cancer and granulocytopenia. 3 Another
controversial issue at that time was whether or not
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vancomycin should be included as part of the empirical
regimen. 4 As there were no differences in outcome
between patients with bacteremia due to Gram-positive
cocci and those without it was concluded that including
vancomycin in the initial empirical antibiotic regimen
was not necessary.
The availability of the broad-spectrum beta-lactam
antibiotics piperacillin and meropenem allowed the
group to explore their effectiveness as empirical therapy
either in combination with amikacin 5 or alone. 6 Hence,
through their efforts the IATCG provided four regimens
that were effective for treating patients who were
granulocytopenic and who had developed fever that had
no obvious infective cause.
The next study was undertaken to see whether or not
an oral regimen of oral ciproﬂoxacin plus amoxicillin–
clavulanate would offer advantages such as improved
quality of life and lower cost over an intravenous
regimen of ceftriaxone plus amikacin. 7 As equivalence
was demonstrated during a planned interim analysis,
the trial was terminated early. Hence, low-risk patients
with cancer who had fever and granulocytopenia could
be given oral therapy and might be able to be managed
further as outpatients.
The group then revisited the issue of coverage for
infections due to Gram-positive cocci and embarked
on a prospective, double-blind trial to see whether
the addition of a glycopeptide reduced the time to
defervescence in neutropenic patients with cancer who
had persistent fever 48−60h after the initiation of
empirical piperacillin/tazobactam therapy. 8 As there was
no measurable beneﬁt to these patients, the practice of
routinely adding vancomycin for persistent fever was
to be discouraged. This had important implications,
given the increase in vancomycin-resistant enterococci
associated with a broad empirical use of vancomycin.
3. Achievements in fungal infections
The IATCG also explored the need for empirical antifun-
gal therapy. There were six documented fungal infections
in 64 (9%) with four deaths in patients randomized to
not receive the antifungal therapy, compared with only
one fungemia and no deaths among the 68 patients (1%)
treated empirically with amphotericin B. Although there
was no statistically signiﬁcant difference in survival
between the two groups, those patients who had not
received any antifungal prophylaxis appeared to beneﬁt
from empirical antifungal therapy.
The newly formed IFIG conducted a prospective,
multicentre surveillance of candidaemia among patients
being treated for cancer. 9 Candida albicans was respon-
sible for most infections involving patients with solid
tumors, but in only 1 out of 3 cases with hematological
malignancies. Neutropenia in solid tumor patients and
acute leukemia, and antifungal prophylaxis in patients
with hematological malignancies were signiﬁcantly
associated with candidemia due to other Candida species.
Mortality was associated with older age, severity of
the underlying disease, fungemia due to C. krusei and
C. glabrata, allogeneic bone marrow transplantation,
septic shock, and the lack of antifungal prophylaxis.
The group then initiated and completed the landmark
trial of voriconazole versus amphotericin B deoxycholate
for the primary therapy of invasive aspergillosis. 10 There
were 144 patients in the voriconazole group and 133
patients in the amphotericin B deoxycholate group with
either deﬁnite or probable aspergillosis, and the majority
had had an allogeneic hematopoietic-cell transplant or
were treated for acute leukemia or other hematological
malignancies. At week 12 successful outcomes were seen
in 1 out of 2 patients given voriconazole and 1 out of 3
given amphotericin B deoxycholate. Seven out of 10 in
the voriconazole group survived as did 6 out of 10 in the
amphotericin B deoxycholate group, but the latter group
experienced more severe drug-related adverse events
(Fig. 1). Consequently, voriconazole became the drug
of choice for treating invasive aspergillosis given the
better responses, improved survival, and fewer severe
side effects. Based on results from this study voricinazole
became the benchmark for other drugs to establish efﬁ-
cacy for treating invasive aspergillosis, and it is regarded
as ﬁrst-line treatment in all guidelines published thus
far. The study itself conﬁrmed that randomized clinical
trials remain the single best instrument for testing drugs
for preventing and treating invasive fungal diseases.
The data generated also provided important information
on the role of imaging 11 and helped to establish an
evidence base for the revised deﬁnitions of invasive
fungal diseases that were published in 2008. 12
4. Major initiatives for worldwide education and
development of guidelines
The IDG has substantially contributed to the develop-
ment of treatment guidelines as well as the worldwide
education, including the web-based education. Clarity
and uniformity in deﬁning infections and providing
guidance for their treatment are important factors both
in the management of patients, as well as in clinical
research, as standardized deﬁnitions strengthen the
consistency and reproducibility of the results. The most
important initiatives of the IDG are the deﬁnitions of
diagnosis for fungal diseases and their treatment and
the development of ECIL guidelines, as discussed below
in more detail.
4.1. Deﬁnitions of invasive fungal diseases
The deﬁnitions for diagnosis of invasive fungal disease
have been developed in collaboration with the Mycosis
Study Group (MSG). The deﬁnitions were originally
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Fig. 1 – Response rates in the modiﬁed intention-to-treat population according to the study protocol, site of infection,
underlying condition, neutropenic status, degree of certainty of the diagnosis, and in the intention-to-treat population.
Results are expressed as the difference (with 95% conﬁdence intervals) between the voriconazole group and the
amphotericin B deoxycholate group in the rate of successful outcomes. 10
published in 2002 13 and the revised version in 2008. 12
The deﬁnitions classify the fungal diseases as “proven,”
“probable,” and “possible” invasive fungal disease. The
category of “proven” invasive fungal disease can apply
to any patient, regardless of whether the patient is
immunocompromised, whereas the “probable” and “pos-
sible” categories are proposed for immunocompromised
patients only. These revised deﬁnitions of invasive fungal
disease are intended to advance clinical and epidemi-
ological research, and may serve as a useful model for
deﬁning other infections in high-risk patients. 12−14 They
have also been adopted by the Committee for Medicinal
Products for Human Use (CHMP) in its “Guideline on the
clinical evaluation of antifungal agents for the treatment
and prophylaxis of invasive fungal disease”. 15
4.2. Deﬁnitions for response to antifungal therapy
Deﬁning the response to antifungal therapy has been
challenging − not least due to the inconsistencies in
previous criteria. Hence deﬁnitions for response to the
treatment of invasive fungal disease were developed
again in collaboration with the Mycosis Study Group.
These deﬁnitions have also been adopted in the
“Guideline on the clinical evaluation of antifungal agents
for the treatment and prophylaxis of invasive fungal
disease”. 16
4.3. European Conference on Infections in Leukaemia (ECIL)
guidelines
In 2005, several groups including the European Group
for Blood and Marrow Transplantation, the IDG from
the European Organization for Treatment and Research
of Cancer, the European Leukaemia Net and the
Immunocompromised Host Society created the European
Conference on Infections in Leukaemia (ECIL). The
main goal of ECIL is to elaborate guidelines or
recommendations for the management of infections in
leukemia and stem cell transplant patients. EORTC IDG
has been the key contributor in the development in these
guidelines. The ECIL guidelines have been published
as three separate sets of publications, ECIL-1 held in
2005, 17−24 ECIL-2 held in 2007, 25,26 and ECIL-3 held in
2009. 27−30 The proceedings of the ECIL-4 conference held
in 2011 will be submitted for publication in 2012.
5. The future of the Infectious Disease Group
At present the group is actively pursuing a large clinical
Phase III strategy study in more than 550 patients.
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This study is expected to increase cross-fertilization
between the different EORTC disease-oriented groups
and enhance future collaboration with other groups with
similar aims and objectives. Collaboration in clinical
research and practice is of paramount importance today,
as the management of infectious complications in cancer
patients is becoming increasingly more complex. Future
challenges include the initiation and completion of
relevant studies not only to attract young investigators
into the ﬁeld but also to consolidate what we have
learned and keep ahead of the new challenges that
face us.
The ﬁeld of infectious diseases is in a constant state
of ﬂux. At present there is a greater understanding of
the role of chemotherapy-induced damage of the mucosa
(mucosal barrier injury) in infection, an appreciation
of the increase in antimicrobial resistance, continuous
changes in the nature of and extent of compromised
immunity related to new ways of treating cancer, and
the increasing number of patients being treated for
cancer as the population ages. At the same time
there are more diagnostic opportunities that include
imaging and molecular techniques. However, the choice
of antimicrobial agents has become more difﬁcult due
to emergent resistance, drug interactions and adverse
effects. Moreover, there are fewer drugs in the pipeline
making it imperative that we learn to use what we
have optimally and sparingly. Funding of health care
also remains an issue as we struggle to provide optimal
care while minimizing costs. This necessitates adoption
of strategies for use and the creation of care pathways
to make the best use of the diagnostic tools and drugs
we have available. The IDG will also maintain a strong
focus on the educational activities and will continue
hosting joint sessions at international conferences in its
own ﬁelds. The group will continue to focus on highly
relevant clinical and translational research activities, as
well as on quality educational projects that meet the
general interests of investigators in the ﬁeld of infectious
complications affecting patients with cancer.
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